FLGT News and Press, Fulgent Genetics Inc. From 11/14/23

Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based company with a well-established clinical diagnostic business and a therapeutic development business, today announced that members of its management team are scheduled to participate ...

Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based company with a well-established clinical diagnostic business and a therapeutic development business, today announced data from two poster presentations being presented tomorrow, Nove...

2023-11-03 12:22:15 ET Fulgent Genetics, Inc. (FLGT) Q3 2023 Earnings Call Transcript November 03, 2023, 08:30 AM ET Company Participants Melanie Solomon - IR Ming Hsieh - CEO Brandon Perthuis - CCO Paul Kim - CFO Lawrence Weiss - Chief Medical Officer ...

2023-11-03 07:08:46 ET More on Fulgent Genetics Fulgent Genetics: Navigating Post-COVID Growing Pains Fulgent Genetics Q3 2023 Earnings Preview Seeking Alpha’s Quant Rating on Fulgent Genetics Historical earnings data for Fulgent Genetics Finan...

HST Global Inc (HSTC) is expected to report for quarter end 2023-09-30 Air China Ltd ADR - Level I (AIRYY) is expected to report for Q3 2023 GrafTech International Ltd. (EAF) is expected to report $-0.05 for Q3 2023 Cardinal Health Inc. (CAH) is expected to report $1.4 for Q1 2024 ...

Core Revenue of $66 million represents Growth of 17% Year-over-Year Additional Reimbursement from COVID-19 Test Sales yields Revenue of $19 million, for Total Revenue of $85 million Reiterates Full Year 2023 Core Revenue Guidance of $260 million Fulgent Genetics, Inc. (NASDAQ: F...

Fulgent Genetics Inc. (FLGT) is expected to report $-0.61 for Q3 2023

2023-11-02 11:29:27 ET More on Fulgent Genetics Fulgent Genetics: Navigating Post-COVID Growing Pains Seeking Alpha’s Quant Rating on Fulgent Genetics Historical earnings data for Fulgent Genetics Financial information for Fulgent Genetics For ...

Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based company with a well-established clinical diagnostic business and a therapeutic development business, today announced two upcoming poster presentations at the Society for Immunotherap...

Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based company with a well-established clinical diagnostic business and a therapeutic development business, today announced that it will release its third quarter 2023 financial results bef...